All | Anti-TNF alone | Anti-TNF + DMARDs | DMARDs alone | |
---|---|---|---|---|
Age (years) | 21 (15–36) | 23 (15–29) | 27 (18–32) | 28 (22–36) |
Gender (male/female) | 12/44 | 3/15 | 6/15 | 3/14 |
Disease duration | 2 (0.17–10) | 0.67 (0.17–3) | 2 (0.75–6) | 7.5 (3.5–10) |
HLA-B27-positive | 91.1 % (51/56) | 88.9 % (16/18) | 90.5 % (19/21) | 94.1 % (16/17) |
Baseline | ||||
SPARCC | 32.45 ± 18.71 | 27.76 ± 18.38 | 39.53 ± 19.21 | 28.67 ± 15.51 |
ASDAS | 2.84 ± 1.26 | 2.56 ± 1.24 | 3.58 ± 1.05 | 2.21 ± 1.03 |
ESRa | 27.10 ± 32.39 | 27.94 ± 33.24 | 38.49 ± 38.50 | 12.14 ± 8.43 |
CRPa | 17.50 ± 23.07 | 16.29 ± 23.05 | 26.29 ± 28.02 | 7.919 ± 5.60 |